Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The substance P/neurokinin 1 receptor pathway is critical in chronic pruritus; anecdotal evidence suggests that antagonism of this pathway can reduce chronic itch. OBJECTIVE: To assess the safety and efficacy of the substance P/neurokinin 1 receptor antagonist serlopitant in treating chronic pruritus. METHODS: Eligible patients with severe chronic pruritus who were refractory to antihistamines or topical steroids were randomized to serlopitant, 0.25, 1, or 5 mg, or to placebo, administered once daily for 6 weeks as monotherapy or with midpotency steroids and emollients. The primary efficacy end point was percentage change in visual analog scale pruritus score from baseline. RESULTS: Serlopitant treatment resulted in a dose-dependent decrease in pruritus. The mean percentage decreases from baseline visual analog scale pruritus scores were statistically significantly larger with the 1- and 5-mg doses of serlopitant (P = .022 and P = .013, respectively) than with placebo at week 6. No significant safety or tolerability differences were detected among the groups. LIMITATIONS: The sample size was insufficient for subgroup analyses of the efficacy of serlopitant for chronic pruritus on the basis of underlying conditions. CONCLUSIONS: Serlopitant, 1 mg and 5 mg daily, was associated with a statistically significant reduction in chronic pruritus and was well tolerated (NCT01951274).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steinhoff, M. S., von Mentzer, B., Geppetti, P., Pothoulakis, C., & Bunnett, N. W. (2014) · Physiological Reviews · doi:10.1152/physrev.00031.2013 · Cited by 628 · cited 1×
“The tachykinin substance P (SP) and its receptor, neurokinin 1 receptor (NK1R), are well established as a pivotal pathway in histamine-independent pruritus.(8,9) Multiple case reports suggest that patients with chronic pruritus respond to treatment with aprepitant,(10-14) the first approved NK1R antagonist.”
BackgroundSelf-citation
Cited by
European S2k Guideline on Chronic Pruritus
Weisshaar, E., Szepietowski, J., Dalgard, F., Garcovich, S., Gieler, U., Giménez-Arnau, A., Lambert, J., Leslie, T., Mettang, T., Misery, L., et al. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3164 · Cited by 405
Self-citationItch: From mechanism to (novel) therapeutic approaches
Yosipovitch, G., Rosen, J. D., & Hashimoto, T. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.09.005 · Cited by 343
Self-citationPerner, C., Flayer, C. H., Zhu, X., Aderhold, P. A., Dewan, Z. N. A., Voisin, T., Camire, R. B., Chow, O. A., Chiu, I. M., & Sokol, C. L. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.001 · Cited by 313
Itch: Pathogenesis and treatment
Sutaria, N., Adawi, W., Goldberg, R., Roh, Y. S., Choi, J., & Kwatra, S. G. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.07.078 · Cited by 130
Ständer, S., Kwon, P., Hirman, J., Perlman, A. J., Weisshaar, E., Metz, M., & Luger, T. A. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.01.052 · Cited by 118
Self-citationPruritus in allergy and immunology
Yang, T.-L. B., & Kim, B. S. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.06.016 · Cited by 112
New and emerging treatments for inflammatory itch
Erickson, S., Heul, A. V., & Kim, B. S. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.05.028 · Cited by 79
The NK1 receptor antagonist serlopitant for treatment of chronic pruritus
Ständer, S., Spellman, M. C., Kwon, P., & Yosipovitch, G. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1638910 · Cited by 26
Self-citation
Metadata
- Authors
- Yosipovitch, G., Ständer, S., Kerby, M. B., Larrick, J. W., Perlman, A. J., Schnipper, E. F., Zhang, X., Tang, J. Y., Luger, T., & Steinhoff, M.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 78
- Issue
- 5
- Pages
- 882-891.e10
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2786913845
- Cited by
- 120
- References
- 1
- FWCI
- 18.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.